The Albanese Government has released its 2023-24 Mid-Year Economic Fiscal Outlook, which includes $3.5 billion since the May Budget for new medicines on the PBS, but also an expected decline in spending on the program that must be qualified because the estimate does not include the impact of future new listings.
Update reveals significant spending on new listings since the May Budget
December 13, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News

